For the year ending 2025-12-31, UTHR had -$140,100K decrease in cash & cash equivalents over the period. $1,040,700K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net income | 1,334,700 |
| Depreciation and amortization | 85,600 |
| Share-based compensation expense | 147,700 |
| Impairments of property, plant, and equipment | 21,700 |
| Deferred income taxes | 97,700 |
| Other | 19,700 |
| Accounts receivable | 70,900 |
| Inventories | 52,600 |
| Accounts payable and accrued expenses | 97,900 |
| Other assets and liabilities | 80,900 |
| Net cash provided by operating activities | 1,561,200 |
| Purchases of property, plant, and equipment | 520,500 |
| Acquired lease intangible assets | 5,500 |
| Deposits | 10,400 |
| Purchases of available-for-sale debt securities | 3,405,400 |
| Maturities of available-for-sale debt securities | 1,583,900 |
| Sales of available-for-sale debt securities | 1,861,600 |
| Purchases of investments in privately-held companies | 55,000 |
| Acquisitions, net of cash acquired | 0 |
| Net cash (used in) provided by investing activities | -551,300 |
| Payments to repurchase common stock | 1,000,000 |
| Proceeds from line of credit | 200,000 |
| Repayment of line of credit | 500,000 |
| Excise tax paid on net share repurchase | 5,000 |
| Payments of debt issuance costs | 11,500 |
| Proceeds from the exercise of stock options | 173,900 |
| Proceeds from the issuance of stock under espp | 9,200 |
| Rsus withheld for taxes | 16,600 |
| Net cash used in financing activities | -1,150,000 |
| Net (decrease) increase in cash and cash equivalents | -140,100 |
| Cash and cash equivalents, beginning of year | 1,697,200 |
| Cash and cash equivalents, end of year | 1,557,100 |
UNITED THERAPEUTICS Corp (UTHR)
UNITED THERAPEUTICS Corp (UTHR)